ALX Oncology Reports the First Patient Dosing in P-I/II (UMBRELLA) Trial of Evorpacept Plus Sarclisa for Treating R/R Multiple Myeloma (RRMM)
Shots:
- ALX Oncology has dosed the first patient in the P-I/II (UMBRELLA) trial of evorpacept (CD47 antigen inhibitor) + Sarclisa (CD38 mAb) for treating r/r multiple myeloma (RRMM)
- The trial is being carried out under a collaboration, with ALX Oncology providing evorpacept & Sanofi providing Sarclisa as well as conducting the study. ALX holds the global commercialization rights of evorpacept
- The P-I/II (UMBRELLA) study to evaluate the safety, efficacy & PK of evorpacept combined with Sarclisa & dexamethasone in RRMM patients, with part 1 determining the recommended evorpacept dose & part 2 finding the combination's effectiveness & safety in a larger patient group
Ref: ALX Oncology | Image: ALX Oncology
Related News:- ALX Oncology Provides Update on P-II (ASPEN-06) Study of Evorpacept to Treat Gastric Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
